Focusing on breast cancer (BC), TG2 inhibition improves the activity of anticancer drugs in the control of cell proliferation and apoptosis [31,32], reverses drug resistance [33] and limits cell motility during epithelial-to-mesenchymal transition (EMT) [14]. The gene discussed is TGM2; the disease is breast carcinoma.